Background: Deriving clinical indications for the HIV nosode by conducting a double-blind, placebo-controlled homeopathic pathogenetic trial (HPT) with the aim to introduce a new nosode to the profession. Method: The HPT was conducted in 22 volunteers, 15 of which received HIV nosode in 30c potency pills, while 7 received identical placebo pills orally, once a week, for 4 weeks. The volunteers' symptoms during initial 7 days of run-in period were noted. All symptoms for both groups produced during run-in period were excluded from final analysis. Informed consent form, approval by Ethics Committee, laboratory investigations as well as safety and ethical measures were provided. The volunteers were trained to write data in prescribed diaries, and the data were analyzed. Results: The HPT of the HIV nosode exhibited qualitatively distinct symptoms, which can be applied in clinical practice. Number of symptoms reported in verum group was 130, in placebo group 60. Quantitative pathogenetic index was 0.285 in verum group, 0.238 in placebo group; qualitative pathogenetic index was 0.1402 in the verum group as compared to placebo (0.0907). Safe use was documented. Conclusion: This study brought in guiding symptoms, which will help the profession to employ this nosode in practice.

Journal Section:
Original Article · Originalarbeit
Keywords:
HIV, Nosode, Homeopathic pathogenetic trial, Drug proving, Double blind, Randomization, Placebo control, Ethics, Quantitative pathogenetic index, Qualitative pathogenetic index
1.
Allen HC: Materia Medica of Nosode. New Delhi, B. Jain, 1988, p. 139.
2.
Luc Montagnier. http://en.wikipedia.org/wiki/Luc_Montagnier (accessed 11.06.2015).
3.
Varma PN: Homeopathic Materia Medica of New Drugs. New Delhi, B. Jain, 2010, p. 20.
4.
Shah R: Hepatitis C Nosode: the preparation and homeopathic pathogenetic trial. Homeopathy 2013;102:207-214.
5.
Shah R: Scientific method of preparing homoeopathic nosodes. Indian J Res Homoeopathy 2014;8:166-174.
6.
Rajpal, Khurana A, Kumar Singh V, et al.: Azadirachta Indica - A multicentric double blind homeopathic pathogenic trial. Indian J Res Homeopathy 2010;4:10-15.
7.
Hahnemann S: Organon of Medicine, ed 6. New Delhi, B. Jain, 1979, p. 190-212.
8.
Central Drug Proving Cum Data Processing Cell, and Pre and Post Trial Medical Report Proforma. New Delhi, Ministry of Health. www.ccrhindia.org/index.asp (accessed 11.06.2015).
9.
Central Council for Research in Homoeopathy: General Directions and Instructions for Proving of Drugs. http://ccrhindia.org/drugprovingintro.asp (accessed 11.06.2015).
10.
European Committee for Homeopathy: Homeopathic Drug Proving Guidelines. www.homeopathyeurope.org/ publications/guidelines/homeopathic-provings/ECH_ Proving_Guidelines_v1.pdf (accessed 11.06.2015).
11.
Indian Council of Medial Research: Ethical Guidelines for Biomedical Research on Human Participants. New Delhi, 2006. http://icmr.nic.in/ethical_guidelines.pdf (accessed 11.06.2015).
12.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. ICH Expert Working Group, 2000. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf (accessed 11.06.2015).
13.
Clinical Trial Registry - India: http://ctri.nic.in (accessed 11.06.2015).
14.
Dean ME, Coulter MK, Fisher P, et al.: Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. Homeopathy 2007;96:42-45.
15.
Dantas F, Fisher P, Walach H, et al.: A systematic review of the quality of homeopathic pathogenetic trials published from 1945 to 1995. Homeopathy 2007;96:4-16.
16.
Shah R: Hydroquinone: homoeopathic pathogenetic trial. Indian J Res Homoeopathy 2013;7:47-61.
17.
Doig GS, Simpson F: Randomization and allocation concealment: a practical guide for researchers. J Crit Care 2005;20:187-193.
18.
United States Food and Drug Administration: Regulatory information. www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312 (accessed 11.06.2015).
19.
Möllinger H, Schneider R, Walach H: Homeopathic pathogenetic trials produce specific symptoms different from placebo. Forsch Komplementmed 2009;16:105-110.
20.
Mycobacterium tuberculosis. http://en.wikipedia.org/wiki/Mycobacterium_tuberculosis (accessed 11.06.2015).
21.
Hering C: The Guiding Symptoms of Our Materia Medica, vol 10. New Delhi, B. Jain, 1989, p. 211, 350.
22.
Boericke W: Pocket Manual of Homoeopathic Materia Medica. New Delhi, B. Jain, 1981, p. 655.
23.
Sarkar BK: Up-to-Dates with Nosodes. Calcutta, Roy Publishing House, 1971, p. 20.
24.
Kent JT: Lectures on Homoeopathic Materia Medica. New Delhi, B. Jain, 1980, p. 1001.
25.
Allen HC: Keynotes and Characteristics with Comparisons of Some of the Leading Rem(e)dies of the Materia Medica with Bowel Nosodes, ed 8. New Delhi, B. Jain, 1990, p. 296.
© 2015 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.